| ［1］ |
Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP［J］. J Dermatol, 2018,45（11）:1235⁃1270. doi: 10.1111/1346⁃8138.14523.
|
| ［2］ |
《脓疱型银屑病诊疗中国专家共识（2022版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）［J］. 中华皮肤科杂志, 2022,55（3）:187⁃195. doi:10.35541/cjd.20210698.
|
| ［3］ |
Bolognia JL, Jorizzo JJ, Schaffer JV, et al. Dermatology. 3rd ed. London: Elsevier, 2012:140.
|
| ［4］ |
Vyas NS, Charifa A, Desman GT, et al. Distinguishing pustular psoriasis and acute generalized exanthematous pustulosis on the basis of plasmacytoid dendritic cells and MxA protein［J］. J Cutan Pathol, 2019,46（5）:317⁃326. doi: 10.1111/cup.13430.
|
| ［5］ |
Kardaun SH, Kuiper H, Fidler V, et al. The histopathological spectrum of acute generalized exanthematous pustulosis （AGEP） and its differentiation from generalized pustular psoriasis［J］. J Cutan Pathol, 2010,37（12）:1220⁃1229. doi: 10.1111/j.1600⁃0560.2010.01612.x.
|
| ［6］ |
Saito Y, Stamp LK, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium （CPIC） guidelines for human leukocyte antigen B （HLA⁃B） genotype and allopurinol dosing: 2015 update［J］. Clin Pharmacol Ther, 2016,99（1）:36⁃37. doi: 10.1002/cpt.161.
|
